deltatrials
Unknown OBSERVATIONAL NCT00005102

Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

Sponsor: Children's Hospital of Philadelphia

Updated 6 times since 2017 Last updated: Jun 23, 2005 Started: Jan 31, 1995
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00005102, this observational or N/A phase trial focuses on Abnormalities, Multiple and Chromosome Abnormalities and remains ongoing. Sponsored by Children's Hospital of Philadelphia, it has been updated 6 times since 1995, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Study Description(click to expand)

PROTOCOL OUTLINE: Blood samples are collected at diagnosis of chromosome 22q11 deletion and assessed for lymphocyte proliferation in response to mitogens phytohemagglutinin, pokeweed mitogen, and concanavalin A (mitogen stimulation analyses). These analyses are repeated at 4 months along with a quantitative analysis of immunoglobulin. At 8 months, patients are tested for their lymphocytes' ability to respond to antigens (candida, tetanus, and diphtheria). At 1 year, patients have lymphocyte subset, IgG, IgA, and IgM analyses performed. Quantitative evaluations of antibody titers to diphtheria, tetanus, Haemophilus influenza, and hepatitis B are also performed. Over 1 year of age, all studies are performed if the patient is seen for a single visit.

PROTOCOL OUTLINE:

Blood samples are collected at diagnosis of chromosome 22q11 deletion and assessed for lymphocyte proliferation in response to mitogens phytohemagglutinin, pokeweed mitogen, and concanavalin A (mitogen stimulation analyses). These analyses are repeated at 4 months along with a quantitative analysis of immunoglobulin.

At 8 months, patients are tested for their lymphocytes' ability to respond to antigens (candida, tetanus, and diphtheria). At 1 year, patients have lymphocyte subset, IgG, IgA, and IgM analyses performed. Quantitative evaluations of antibody titers to diphtheria, tetanus, Haemophilus influenza, and hepatitis B are also performed.

Over 1 year of age, all studies are performed if the patient is seen for a single visit.

Status Flow

~Jan 2017 – ~Apr 2018 · 15 months · monthly snapshotUnknown Status~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 19 months · monthly snapshotUnknown

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown StatusUnknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status

  5. Apr 2018 — Jun 2018 [monthly]

    Unknown Status

    Phase: NANone

Show 1 earlier version
  1. Jan 2017 — Apr 2018 [monthly]

    Unknown Status NA

    First recorded

Jan 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Children's Hospital of Philadelphia
  • National Center for Research Resources (NCRR)
Data source: National Center for Research Resources (NCRR)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations